Male Breast Cancer
Male Occult Triple-negative Breast Cancer With Dermatomyositis: A Case Report and Review of the LiteratureDecember 29, 2017
[OncoTargets and Therapy] In this case report, a patient with male breast cancer developed dermatomyositis.
Breast cancer survivors who received taxane-based chemotherapy for their disease are at increased risk for falls due to CIPN and treatment-associated effects on balance and gait.
Male breast cancer patients are less likely than their female counterparts to receive adjuvant hormone therapy and postlumpectomy radiation.
[Breast Cancer: Targets and Therapy] This review examines clinical characteristics of male breast cancer and best practices for long-term care with a focus on surveillance, screening, and treatment-related symptom management.
Results from the largest series of male breast cancer cases ever studied shows improvement in male survival, but not equal to that seen in women with breast cancer.
Breast cancer is treated differently in men than in women, with regard to frequency of both mastectomy and radiation treatment.
Breast cancer affects men as well as women, and the men who live with and survive breast cancer have a number of gender-specific adjustments to make.
Sign Up for Free e-newsletters
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- When There Are No Words: Interpreting Patients' and Families' Subtle Messages
- Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|